|
WO2020219464A1
|
|
Cyclic phosphate compounds
|
|
WO2020214834A1
|
|
Crystalline forms and methods of producing crystalline forms of a compound
|
|
WO2019139919A1
|
|
Acetal compounds and therapeutic uses thereof
|
|
US2019194143A1
|
|
Glucagon receptor antagonists
|
|
US2016297824A1
|
|
Imidazo-fused heterocycles and uses thereof
|
|
CN107295800A
|
|
Gemcitabine derivative
|
|
US2017158725A1
|
|
Prodrug compounds and uses therof
|
|
US2017216229A1
|
|
Glucagon antagonists
|
|
AU2015217221A1
|
|
Prodrug compounds and their uses
|
|
EP3613418A1
|
|
Methods and compositions for modulating hormone levels
|
|
WO2015077368A1
|
|
Derivatives of uridine 5'-cyclophosphate useful to treat hepatitis c viral infections
|
|
WO2014150252A1
|
|
Methods of treatment associated with the granulocyte colony-stimulating factor receptor
|
|
WO2014043380A1
|
|
Novel nucleotide prodrug compounds and use
|
|
WO2013134311A1
|
|
Steroid hormone and cholesterol pathways as one unified homestatic system
|
|
WO2013106344A1
|
|
2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
|
|
EP2780322A1
|
|
Methods and compositions associated with the granulocyte colony-stimulating factor receptor
|
|
WO2013025628A1
|
|
Janus kinase inhibitor compounds and methods
|
|
AU2011265475A1
|
|
Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
|
|
CN103298792A
|
|
Heterocycle amines and uses thereof
|
|
EP2642994A2
|
|
Use of hematopoietic growth factor mimetics
|
